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The effects of antenatal depression and antidepressant treatment during pregnancy on
both mother and child are vigorously studied, but the underlying biology for these effects
is largely unknown. The placenta plays a crucial role in the growth and development
of the fetus. We performed a gene expression study on the fetal side of the placenta
to investigate gene expression patterns in mothers with antenatal depression and
in mothers using antidepressant treatment during pregnancy. Placental samples from
mothers with normal pregnancies, from mothers with antenatal depression, and from
mothers using antidepressants were collected. We performed a pilot microarray study
to investigate alterations in the gene expression and selected several genes from the
microarray for biological validation with qPCR in a larger sample. In mothers with
antenatal depression 108 genes were differentially expressed, whereas 109 genes were
differentially expressed in those using antidepressants. Validation of the microarray
revealed more robust gene expression differences in the seven genes picked for
confirmation in antidepressant-treated women than in depressed women. Among the
genes that were validated ROCK2 and C12orf39 were differentially expressed in both
depressed and antidepressant-treated women, whereas ROCK1, GCC2, KTN1, and
DNM1L were only differentially expressed in the antidepressant-treated women. In
conclusion, antenatal depression and antidepressant exposure during pregnancy are
associated with altered gene expression in the placenta. Findings on those genes picked
for validation were more robust among antidepressant-treated women than in depressed
women, possibly due to the fact that depression is a multifactorial condition with varying
degrees of endocrine disruption. It remains to be established whether the alterations
found in the gene expression of the placenta are found in the fetus as well.
Keywords: antenatal depression, antidepressants, fetal, placenta, gene expression, microarray
INTRODUCTION
Unfortunately pregnancy is not a lighthearted period for all
women. About 10% of pregnant women in economically devel-
oped countries and up to 25% of pregnant women in poorer
countries develop symptoms of depression, such as fatigue, trou-
ble sleeping, sense of sadness or hopelessness, during pregnancy
(O’Keane and Marsh, 2007). The 5th edition of the Diagnostic
and Statistical Manual of Mental Disorders (DSM-V) also
acknowledged the peripartum onset of depression (American
Psychiatric Association, 2013). Antenatal depression is not only
affecting the mother’s well-being but also affects the unborn
child and has been associated with child internalizing difficulties
(Barker et al., 2011), attention problems (Van Batenburg-Eddes
et al., 2012), and violent behavior during adolescence (Hay
et al., 2010). Moreover, the risk of developing depression during
adolescence (Pawlby et al., 2009) or adulthood (Pearson et al.,
2013) is higher. Although the genetic setup of the mother,
the hormonal/reproductive history, current stressors, and life
experiences are known risk factors (Miller and LaRusso, 2011),
the underlying biological mechanisms of antenatal depression
and especially its influence on the developing child remain
largely unknown. So far one of the mainly suggested biological
mechanism underlying the effects of antenatal depression is the
activation of the HPA-axis (reviewed in: Field, 2011; Olivier
et al., 2014; Waters et al., 2014). In addition to increased cortisol
levels Field et al. (2004) also reported on reduced serotonin
and dopamine levels in urine samples of depressed pregnant
women. Alterations in cortisol/HPA axis responses or in cate-
cholamines/serotonin may explain some effects in the offspring,
however the intrauterine environment is directly passed into
the embryo-fetal epigenetic programming. For this reason
exposure to antenatal depression in utero may also increase the
risk for adverse outcome in the offspring via epigenetic alter-
ations (Babenko et al., 2015). Several treatments for antenatal
depression are available, including antidepressant treatment.
Antidepressants pass the placenta and are found in the amniotic
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fluid (Hostetter et al., 2000; Loughhead et al., 2006). Although
the exact effect on the offspring is unknown, the use of antide-
pressants during pregnancy has increased during the last decades.
From 1998 to 2005 a 300% increase in antidepressant use during
pregnancy was reported (Alwan et al., 2011) and this number is
still increasing. Selective serotonin reuptake inhibitors (SSRIs)
are the most frequently used antidepressants during pregnancy
(Andrade et al., 2008), and are generally considered safe (Gentile,
2005). However, epidemiologic studies have found associations
between SSRI use and neurodevelopmental disorders, e.g.,
autism (Croen et al., 2011; Rai et al., 2013), and attention-deficit
hyperactivity disorder (Clements et al., 2014). Cohort studies
are underway for the study of SSRI use during pregnancy and
the neurodevelopmental disorders in the offspring (Malm et al.,
2012). Although some SSRI effects during pregnancy have been
reported in the offspring (see: Olivier et al., 2013; Bourke et al.,
2014) there is still a great need to investigate the molecular mech-
anisms involved in antenatal depression that may be altered by
antidepressants. By unraveling these pathways we generate more
insight into the effects of antenatal depression and antidepressant
treatment on the developing child, which ultimately helps in
future decisions of using antidepressants during pregnancy.
The placenta plays a pivotal role in supporting fetal growth
and development and is a crucial regulator of maternal-fetal
interactions and fetal brain development (Hsiao and Patterson,
2012). In fact, placental serotonin synthesis directly modulate
fetal brain development (Bonnin et al., 2011). As the placenta car-
ries important information about the pregnancy, investigation of
the placenta provides valuable insight to the molecular mecha-
nisms that may have both immediate and long lasting effects on
fetal health. This study was designed as a hypothesis-generating
study and investigated the impact of antenatal depression and
antidepressant treatment during pregnancy on the gene expres-
sion in the fetal placenta. Placental samples from mothers with
normal pregnancies, from mothers with antenatal depression,
and from mothers using antidepressants were collected from the
“Biology, Affect, Stress, Imaging and Cognition in Pregnancy
and the Puerperium” (BASIC) project. In a first pilot microarray
experiment 108 genes were differentially expressed in antena-
tal depressed mothers whereas 109 genes were differentially
expressed in those using antidepressants. Of these genes, seven
were chosen for biological validation in a larger sample.
MATERIALS AND METHODS
SUBJECTS
This study was carried out at the Department of Women’s
and Children’s health, Uppsala University Hospital, as part of
an ongoing longitudinal study on antenatal and postpartum
depression: the Biology, Affect, Stress, Imaging and Cognition
in Pregnancy and the Puerperium (BASIC) project. The BASIC
project started in 2010 and aims to include a study population
of 5000 pregnant women in the Uppsala County. Women attend-
ing the routine ultrasound examination (gestational week 16–17)
at Uppsala University Hospital are approached for participation,
enabling a population-based sampling. Upon informed consent,
women fill out web-based questionnaires in gestational week 17
and 32 including questions on physical and socio-demographic
characteristics, medical, psychiatric, gynecologic and obstet-
ric history variables, lifestyle, medication parameters, and the
Swedish version of the Edinburgh Postnatal Depression Scale
(EPDS). Information concerning the maternal depression, SSRI
use, delivery and neonatal outcome were retrieved from the
medical records. Placental biopsies are collected at delivery.
For the specific aim of this sub-study, inclusion criteria were
women of Caucasian origin, normal pregnancies and deliver-
ies and healthy offspring (no diagnoses and no admittance to
neonatal care). Exclusion criteria were smoking or alcohol use
during pregnancy, any daily use of prescribed drugs during
pregnancy, any other chronic condition or disease, gestational
age <35 weeks, and maternal age <18 or >42 years. Women on
antidepressants used their treatment during the entire pregnancy
in clinically relevant doses (low-dose use was excluded). The
study was approved by the Regional Ethics Committee, Uppsala,
Sweden, and performed in accordance with relevant guidelines
and regulations.
Study population for micro-array analysis
Women with pregnancies complicated by ongoing depression
(n = 5), SSRI treatment (n = 5) and women with normal
pregnancies (n = 10) were selected from the BASIC biobank.
Depressed women had medical records confirming major depres-
sion and ongoing treatment for their depression in terms
of psychotherapy. In the SSRI group sertraline (n = 3), flu-
oxetine (n = 1) and escitalopram (n = 1) was used. Women
on SSRIs displayed significantly lower depression scores than
depressed women, i.e., the two groups were not readily compa-
rable (Table 1). Hence, the exposure of ongoing depression or
SSRI treatment, respectively, were compared against two con-
trol groups. Controls were matched with respective depressed or
SSRI-treated women by age (±2 years), BMI (±one unit) and
gestational length (±1 week) on an individual level. The control
group consisted of women with no history and no current symp-
toms/diagnoses of mood or anxiety disorders, and their EPDS
scores at gestational week 17 and 32 were 6 or lower.
Study population for validation of the microarray
The samples described above were extended to 24 women
with pregnancies complicated by ongoing depression, 29
antidepressant-treated women and 31 women with normal preg-
nancies. The depressed group included the five microarray cases
and 18 women with EPDS >12 in gestational week 17 and
32, or an EPDS score >14 on at least one time point (n = 1).
The average EPDS score for all depressed women was >15 in
gestational week 17 and 32. The EPDS questionnaire is vali-
dated for use in both pregnant and postpartum women (Gibson
et al., 2009), and has been validated for the Swedish setting
(Rubertsson et al., 2011). The EPDS contains ten items (rated
on a scale from 0 to 3), based on the past 7 days. While its
sensitivity is relatively low, a cut-off score of >12 points dur-
ing pregnancy has a specificity of 98–99% for major depres-
sion (Bergvink et al., 2011). Thirteen of the depressed women
were also evaluated by Mini International Neuropsychiatric
Interview, which confirmed that all but one (she had social pho-
bia) had major depressive disorder during pregnancy. In the
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Table 1 | Microarray demographic variables in the depressed group, SSRI group, and healthy controls.
Depressed Women (n = 5) Healthy controls (n = 5) SSRI-treated Women (n = 5) Healthy controls (n = 5)
Age (years) 31.4 ± 2.2 31.2 ± 2.4 29.2 ± 3.4 29.0 ± 3.0
Parity (n, median, range) 1 (0-2) 0 (0-1) 0 (0-2) 0 (0-2)
BMI (kg/m2) 22.8 ± 3.0 23.5 ± 2.5 26.9 ± 5.8 24.5 ± 4.1
Birth weight (gram) 3542 ± 461 3632 ± 342 3538 ± 225 3556 ± 275
Gender offspring (% boy) 60 40 20 80
Gestational length 276 ± 11 283 ± 5 275 ± 3 277 ± 5
EPDS score week 17 14.8 ± 7.3a 2.6 ± 1.8 8.0 ± 3.2 3.4 ± 1.6
EPDS score week 32 18.8 ± 5.3b 3.2 ± 1.6 6.3 ± 3.4 4.0 ± 1.2
Data presented as mean ± SD or median (range).
asignificantly greater than both control groups, P < 0.01, ANOVA post hoc Bonferroni.
bsignificantly greater than all other groups, P < 0.001, ANOVA post hoc Bonferroni.
antidepressant-treated group, women used sertraline (n = 11),
fluoxetine (n = 8), citalopram/escitalopram (n = 7), venlafaxine
(n = 2) and clomipramine (n = 1). Treatment had been initiated
by primary care physicians as well as by psychiatrists.
SAMPLE COLLECTION, PROCESSING, AND STORING
Placental tissues (containing both maternal and fetal side) were
obtained after delivery, rinsed carefully in sterile phosphate-
buffered saline to wash off maternal and fetal blood, and frozen
on dry ice within 60min of delivery and stored at −70◦C until
further use. Each placenta was individually processed as a single
biological replicate in the microarray and validation study.
RNA ISOLATION
Microarray study
A biopsy was taken with a 3mm cube from the fetal side
of the placenta. Total RNA was isolated using miRNeasy mini
kit (Qiagen, Hilden, Germany). Tissue was lysed with QIAzol
reagent (Qiagen) using a rotor-stator homogenizer (up to
33.000 rpm; Ingenieursbu˝ro CATM Zipper Gmbh, type x120,
Staufen, Germany) and chloroform (Sigma Aldrich, St. Louis,
MO, USA) was added for phase-separation. The rest of the
procedure was performed as described in manufactures protocol.
Validation study
A biopsy was taken from the fetal side of the placenta with a 3mm
cube. Total RNA was isolated using RNeasy mini (Qiagen, Hilden,
Germany). Tissue was lysed with QIAzol reagent (Qiagen) using
TissueLyser (20Hz, 2 × 5min) with stainless steel beads (Qiagen)
and chloroform was added for phase-separation. The rest of the
procedure was performed as described in manufactures protocol.
For both studies RNA concentration was measured with ND-
1000 spectrophotometer (NanoDrop Technologies, Wilmington,
Delaware, USA) and RNA quality was evaluated using the Agilent
2100 Bioanalyzer system (Agilent Technologies Inc, Palo Alto,
California, USA).
MICROARRAY EXPRESSION ANALYSIS
250 nanograms of total RNA from each sample were used to
generate amplified and biotinylated sense-strand cDNA from the
entire expressed genome according to the AmbionWTExpression
Kit (P/N 4425209 Rev B 05/2009) and Affymetrix GeneChip®WT
Terminal Labeling and Hybridization User Manual (P/N 702808
Rev. 4, Affymetrix Inc., Santa Clara, CA). GeneChip® ST Arrays
(GeneChip® XXX Gene 1.0 ST Array) were hybridized for 16 h in
a 45◦C incubator, rotated at 60 rpm. According to the GeneChip®
Expression Wash, Stain and Scan Manual (PN 702731 Rev 3,
Affymetrix Inc., Santa Clara, CA) the arrays were thenwashed and
stained using the Fluidics Station 450 and finally scanned using
the GeneChip® Scanner 3000 7G.
MICROARRAY DATA ANALYSIS
The raw data was normalized in the free software Expression
Console provided by Affymetrix (http://www.affymetrix.com)
using the robust multi-array average (RMA) method first sug-
gested by Li and Wong (2001) and Irizarry et al. (2003).
Subsequent analysis of gene expression data was carried out in
the freely available statistical computing language R (http://www.
r-project.org) using packages available from the Bioconductor
project (www.bioconductor.org). In order to search for differen-
tially expressed genes between the depressed and controls, and
the SSRI and the control groups an empirical Bayes moderated
t-test with robust regression was applied (Smyth, 2004), using
the “limma” package (Smyth, 2005). To address the problem of
multiple testing, p-values were adjusted according to Benjamini
and Hochberg (1995). The Genesis software, version 1.7.1 (http://
genome.tugraz.at/), was used to produce hierarchical cluster-
ing and to visualize differentially expressed genes by heat maps
(Sturn et al., 2002). The expression data were further analyzed
using ingenuity pathway analysis (IPA) in order to determine sig-
nificantly deregulated genes and pathways (Ingenuity® Systems,
Mountain View, CA, USA; www.ingenuity.com). IPA reveals Top
genes, which are genes with the largest normalized enrichment
scores, and IPA computes a score for each network according to
the fit of that network to the user-defined set of Focus Genes.
The score, derived from a p-value, indicates the likelihood of the
association between the set of focus genes (Bonferroni-corrected
significance threshold of P < 0.05 and a fold change of 0.5) and
a given pathway. The smaller the p-value, the less likely that the
association is found due to random chance. In general P-values
below 0.05 indicate a non-random significant association. The
p-value is calculated using the right-tailed Fisher Exact Test (for
more details see www.ingenuity.com).
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cDNA SYNTHESIS
cDNA was synthesized using SuperScriptIII reversed transcrip-
tase (Invitrogen, Carlsbad, California, USA) according to man-
ufacturer’s protocol. Briefly, 250 ng of total RNA was used to
reverse transcribe using the random primer to prepare 20μl of
cDNA.
REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE
CHAIN REACTION ANALYSIS
The validity of the microarray results was tested via quan-
titative real-time PCR (qRT-PCR) employing the StepOne
Plus qPCR machine (Applied Biosystems, Life Technologies,
Carlsbad, California, USA). For validation we selected seven
genes [NEXN (Hs00332124_m1), GCC2 (Hs00206083_m1),
ROCK 1 (Hs01127699_m1), ROCK2 (Hs00178154_m1), DNM1
(Hs00247147_m1), KTN1 (Hs00192160_m1), and C12ORF39
(Hs00228976_m1)] which showed a fold change (FC) > 0.5
in the microarray. GAPDH (Hs99999905_m1) and β-actin
(4326315E) were selected as reference genes for normalization.
cDNA of the samples was used for quantification. TaqMan Gene
expression Assay primers, probes and gene expression master
mix (all Applied Biosystems, Life Technologies, Carlsbad, CA,
USA) were used to run the qRT-PCR according to manufac-
turer’s instructions. Mean plate efficiencies were calculated by
LinReg.
qPCR DATA ANALYSIS
All samples were performed in triplicates and averaged for fur-
ther calculations. Mean normalized expression (MNE) based on
the ratio between Ct-values of target and reference genes and the
efficiency of the PCR reactions, was calculated as a measure of
target gene transcription, as described previously (Muller et al.,
2002; Helmestam et al., 2012). Data are presented as log2 MNE to
illustrate the difference between the groups.
STATISTICS
Clinical characteristics of women in the microarray study and
the validation study were compared by means of One-Way
ANOVA, followed by a Bonferroni post hoc test when appropri-
ate. Differences in expression between subsets in the validation
study (qPCR) were calculated using a univariate ANOVA with
age, BMI, parity, and week of delivery as covariates. Data were
analyzed using the SPSS 20.0 software. Level of significance was
set at P < 0.05. Data are presented as mean ± S.E.M.
RESULTS
SUBJECTS
The demographic characteristics of the women in the microar-
ray and validation studies are presented in Tables 1, 2.Microarray
study: A significant group difference was found for EPDS scores
at gestational week 17 [F(3, 18) = 8.9, P < 0.01] and gestational
week 32 [F(3, 17) = 22.8, P < 0.001]. Depressed women had sig-
nificantly higher EPDS scores in gestational week 17 and 32
compared with controls (P < 0.01), whereas women on SSRIs did
not differ from controls at any time-point. In gestational week
32, depressed women also had significantly higher EPDS scores
than SSRI-treated women, Table 1. Validation study: All women
on SSRI treatment reported previous anxiety and/or depression
at the first antenatal booking, whereas 41% of depressed cases
had no previous psychiatric history. Women using antidepres-
sants had a significantly shorter gestational length than con-
trols (P < 0.01). As expected, significant group differences were
found in EPDS scores at gestational weeks 17 [F(2, 74) = 69.6,
P < 0.001] and 32 [F(2, 74) = 74.3, P < 0.001]. In gestational
week 17 and 32, depressed women had significantly higher EPDS
scores than antidepressant-treated women (P < 0.001 and P <
0.001, respectively), whom in turn had higher EPDS scores than
controls (P < 0.001 and P < 0.001, respectively), Table 2. No
other parameters differed between groups.
Table 2 | Validation demographic variables in the depressed group, SSRI group, and healthy controls.
Healthy controls (n = 31) Depressed women (n = 24) SSRI-treated Women (n = 29)
Age (years) 31.4 ± 3.9 31.1 ± 4.3 31.2 ± 4.1
Parity (n, median, range) 0 (0-3) 1 (0-2) 1 (0-3)
BMI (kg/m2) 26.0 ± 4.9 24.0 ± 6.2 27.2 ± 4.9
Systolic blood pressure in first trimester, mmHg 119 ± 13 111 ± 12 118 ± 12
Diastolic blood pressure in first trimester, mmHg 73 ± 9 69 ± 7 70 ± 7
Systolic blood pressure at last visit, mmHg 125 ± 11 119 ± 11 125 ± 10
Diastolic blood pressure at first visit, mmHg 79 ± 8 76 ± 6 77 ± 7
Lowest hemoglobin level during pregnancy, g/dl 11.7 ± 0.8 11.4 ± 0.8 11.0 ± 0.9c
Birth weight (gram) 3577 ± 351 3546 ± 499 3589 ± 400
Gender offspring (% boy) 65 54 45
Gestational length 281 ± 7 275 ± 11 273 ± 8c
EPDS score week 17 2.9 ± 1.8 15.0 ± 4.2a 7.7 ± 4.9b
EPDS score week 32 2.9 ± 1.8 15.9 ± 3.6a 8.7 ± 5.3bd
Data presented as mean ± SD or median (range).
asignificantly higher than all other groups, P < 0.001, ANOVA post hoc Bonferroni.
bsignificantly higher than healthy control group, P < 0.001, ANOVA post hoc Bonferroni.
csignificantly lower than healthy control group, P < 0.01, ANOVA post hoc Bonferroni.
d significantly lower than depressed group, P < 0.001, ANOVA post hoc Bonferroni.
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DIFFERENTIALLY EXPRESSED GENES AND PATHWAYS BETWEEN THE
DEPRESSED AND CONTROL PLACENTAS
At a Bonferroni-corrected significance threshold (P < 0.05) and
a log2-fold change of 0.5 or higher we found 108 genes dif-
ferentially expressed between the depressed women and their
respective controls; 100 were down-regulated and 8 up-regulated,
see Table 3. The raw microarray data is found as an excel file in
the Supplementary Data. The ingenuity pathway analysis (IPA)
revealed 17 differentially expressed top genes; 7 were up-regulated
and 10 down-regulated. Top up- and down-regulated molecules
are summarized in Table 4. We then clustered placentas according
to their gene expression profiles for the 17 genes that dis-
played differential expression (see Figure 1A). In order to deter-
mine the biological relevance, analysis with IPA was performed,
focusing on genes that differed in expression between placen-
tas from depressed women and controls. As shown in Table 5,
we identified five gene networks that were significantly enriched,
classified as follows: (I) DNA Replication, Recombination, and
Repair, Cellular Assembly and Organization, Cell Cycle with
an IPA score of 27; (II) Cell Cycle, Cancer, Connective Tissue
Disorders with a IPA score of 18; (III) Cellular movement,
Hematological System Development and Function, Immune Cell
Trafficking with an IPA score of 16; (IV) Cardiovascular System
Development and Function, Organismal Development, Visual
System Development and Function with an IPA score of 14; and
(V) Molecular Transport, RNA Trafficking, Connective Tissue
Disorders with an IPA score of 9 (Table 5). Further, the sig-
nificant canonical pathways identified by IPA (P < 0.05) are
shown in Table 6, along with the included genes and p-values.
Pathways included Actin Nucleation by ARP-WASP Complex,
RhoA Signaling, VEGF Signaling, Protein Kinase A Signaling,
and 1D-myo-inositol Hexakisphosphate Biosynthesis V [from
Ins(1,3,4)P3].
DIFFERENTIALLY EXPRESSED GENES AND PATHWAYS BETWEEN
SSRI-TREATED AND CONTROL PLACENTAS
Similarly, we found 109 genes to be differentially expressed
between the SSRI-treated women and their respective controls
at a Bonferroni-corrected significance (P < 0.05) threshold with
a fold change of 0.5 or higher. 82 genes were down-regulated
and 27 up-regulated, see Table 7. The raw microarray data is
found as an excel file in the Supplementary Data. IPA analy-
sis revealed 20 differentially expressed top genes, of which 10
were up- and 10 down-regulated (see Table 8). We then clus-
tered placentas according to their gene expression profiles for the
20 genes that displayed differential expression (see Figure 1B).
With use of IPA we focused on genes that differed in expres-
sion between placentas from antidepressant-treated women and
controls. As shown in Table 9, we identified five gene net-
works that were significantly enriched. Of biological relevance
were: (I) Infectious Disease, Cellular Assembly and Organization,
Cellular Function and Maintenance with an IPA score of 13;
(II) Cellular Growth and Proliferation, Inflammatory Response,
Lipid Metabolism with an IPA score of 11; (III) Cell Death and
Survival, Inflammatory Response, Cellular Movement with an
IPA score of 9; (IV) Cell death and Survival, Liver Necrosis/Cell
Death, Hematological System Development and Function with
an IPA score of 8; and (V) Cardiovascular Disease, Skeletal and
Muscular Disorders, Cardiovascular System Development and
Function with an IPA score of 2. Further, the significant canon-
ical pathways identified by IPA (P < 0.05) are shown in Table 10,
along with the included genes and p-values. Pathways included
Ephrin A Signaling, RhoA Signaling, PEDF Signaling, Breast
Cancer Regulation by Stathmin1, and Signaling by Rho Family
GTPases.
COMMONLY ALTERED GENES IN DEPRESSED AND SSRI-TREATED
GROUPS
Of the 108 genes that were differentially expressed between the
depressed and the control cases, and the 109 genes that were dif-
ferentially expressed between the SSRI-treated and the control
cases, only 20 genes were overlapping. These genes are displayed
in Table 11.
VALIDATION OF MICROARRAY DATA USING qPCR ANALYSIS
For validation of the microarray results we selected seven genes
that were detected in top up- or down-regulated genes, in the
pathway analysis or in the canonical pathway analysis in placen-
tal tissue of both depressed and antidepressant-treated women.
ROCK1 and ROCK2 are both involved in the actin nucleation
by ARP-WASP complex, RhoA signaling, VEGF Signaling and
protein kinase A signaling in the canonical pathway analysis of
depressed women. Moreover they also appeared in the canoni-
cal pathway analysis of ephrin A Signaling, RhoA signaling, PEDF
signaling, breast cancer regulation by stathmin 1 and signaling by
Rho family GTPases of antidepressant-treated women. In addi-
tion, ROCK1 and GCC2 belonged to the top down-regulated
genes in depressed as well as antidepressant-treated women and
ROCK2 is a top down-regulated gene in the depressed women as
well. KTN1 is involved in molecular transport, RNA trafficking,
connective tissue disorders pathway of depressed women, but also
in infectious disease, cellular assembly and organization, cellu-
lar function and maintenance pathway of antidepressant-treated
women. Moreover, KTN1 is involved in the RhoA signaling of the
canonical pathway analysis in both depressed and antidepressant
women. DNM1L is involved in cardiovascular system develop-
ment and function, organismal development, visual system devel-
opment and function of the pathway analysis in depressed women
but also in cell death and survival, inflammatory response, cellu-
lar movement pathway analysis of antidepressant-treated women.
NEXN was the top down-regulated gene in antidepressant-
treated women and also turned out to be involved in cardio-
vascular disease, skeletal and muscular disorders, cardiovascular
system development and function pathway in antidepressant-
treated women. Finally, C12orf39 was chosen as it appeared
to be the top up-regulated gene in antidepressant-treated
women.
In the placenta of depressed women (Figure 2A) a significant
down-regulation compared to placenta of controls was found for
the C12orf39 gene [F(1, 45) = 3.83, p = 0.05] and a tendency for
down-regulation of the ROCK2 gene was found [F(1, 44) = 3.03,
p = 0.08]. No other genes were differentially expressed between
control and depressed placentas (NEXN [F(1, 45) = 0.57], GCC2
[F(1, 45) = 0.52], ROCK1 [F(1, 45) = 2.43], DNM1L [F(1, 45) =
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Table 3 | Significantly up and down regulated genes in the control vs. depressed groups (− = reduction in expression levels).
Gene symbol Gene name Probe ID Log2 fold change
VTRNA1-2 vault RNA 1-2 8108629 2.280673826
PGF placental growth factor 7980233 0.695475147
RNH1 /// FLJ23519 ribonuclease/angiogenin inhibitor 1 /// hypothetical protein FLJ23519 7945420 0.565671098
ITPK1 inositol 1,3,4-triphosphate 5/6 kinase 7980970 0.549075065
mir503 − 8175261 0.519417648
RAD23A RAD23 homolog A (S. cerevisiae) 8026122 0.51907744
FAM183B acyloxyacyl hydrolase (neutrophil) 8139160 0.50922813
APOC1 apolipoprotein C-I 8029536 0.502399918
KIR3DL2 /// KIR2DS2 /// KIR2DL2 ///
KIR2DL1 /// KIR2DS4 /// KIR2DL3 ///
LOC727787 /// KIR2DS5
killer cell immunoglobulin-like receptor, three domains, long
cytoplasmic tail, 2 /// killer cell immunoglobulin-like receptor, two
domains, short cytoplasmic tail, 2 /// killer cell immunoglobulin-like
receptor, two domains, long cytoplasmic tail, 2 /// killer cell
immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1
/// killer cell immunoglobulin-like receptor, two domains, short
cytoplasmic tail, 4 /// killer cell immunoglobulin-like receptor, two
domains, long cytoplasmic tail, 3 /// similar to killer cell
immunoglobulin-like receptor 3DL2 precursor (MHC class I NK cell
receptor) (Natural killer-associated transcript 4) (NKAT-4) (p70 natural
killer cell receptor clone CL-5) (CD158k antigen) /// killer cell
immunoglobulin-like receptor, two domains, short cytoplasmic tail, 5
8031293 −0.506084964
SNX4 sorting nexin 4 8090256 −0.506251931
NEK1 NIMA (never in mitosis gene a)-related kinase 1 8103646 −0.50748106
RALGPS2 Ral GEF with PH domain and SH3 binding motif 2 7907657 −0.508099708
RNF160 ring finger protein 160 8069711 −0.50811689
− − 8104012 −0.508994997
RIF1 RAP1 interacting factor homolog (yeast) 8045697 −0.511151224
LRP2 low density lipoprotein-related protein 2 8056611 −0.513852689
PTBP2 polypyrimidine tract binding protein 2 7903188 −0.517797539
ZMAT1 zinc finger, matrin type 1 8174119 −0.519592242
RUFY2 RUN and FYVE domain containing 2 7933999 −0.524450233
SNAPC1 small nuclear RNA activating complex, polypeptide 1, 43kDa 7974870 −0.52596952
RNF19A ring finger protein 19A 8152041 −0.526515918
SKIV2L2 superkiller viralicidic activity 2-like 2 (S. cerevisiae) 8105353 −0.530773126
ANAPC4 anaphase promoting complex subunit 4 8094408 −0.533126207
− − 7916667 −0.533554256
NCKAP1 NCK-associated protein 1 8057517 −0.53822831
DGKH diacylglycerol kinase, eta 7968800 −0.538998035
MARCH7 membrane-associated ring finger (C3HC4) 7 8045919 −0.550742909
HOMER1 homer homolog 1 (Drosophila) 8112841 −0.551657356
PHF20L1 PHD finger protein 20-like 1 8148358 −0.551986952
YEATS4 YEATS domain containing 4 7957032 −0.55366204
CHRM3 cholinergic receptor, muscarinic 3 7910915 −0.554183212
PDE3B phosphodiesterase 3B, cGMP-inhibited 7938629 −0.557038965
BRMS1L breast cancer metastasis-suppressor 1-like 7973948 −0.55836529
SNORD30 small nucleolar RNA, C/D box 30 7948900 −0.560928764
ZNF84 zinc finger protein 84 7960143 −0.562597276
MND1 meiotic nuclear divisions 1 homolog (S. cerevisiae) 8097857 −0.5650204
LOC221442 adenylate cyclase 10 pseudogene 8119423 −0.565773386
UBA6 ubiquitin-like modifier activating enzyme 6 8100615 −0.566611488
N4BP2L2 NEDD4 binding protein 2-like 2 7970907 −0.570303348
ZRANB2 zinc finger, RAN-binding domain containing 2 7916969 −0.573773594
EIF5B eukaryotic translation initiation factor 5B 8043861 −0.574408988
NAP1L1 nucleosome assembly protein 1-like 1 7965048 −0.581711065
(Continued)
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Table 3 | Continued
Gene symbol Gene name Probe ID Log2 fold change
ZNF146 zinc finger protein 146 8028186 −0.584609444
BRWD3 bromodomain and WD repeat domain containing 3 8173766 −0.592331241
KIAA1109 KIAA1109 8097148 −0.602191356
SENP7 SUMO1/sentrin specific peptidase 7 8089203 −0.603487152
FZD6 frizzled homolog 6 (Drosophila) 8147766 −0.605426406
CHD9 chromodomain helicase DNA binding protein 9 7995583 −0.607612535
KIAA1430 KIAA1430 8103979 −0.617503882
RNF217 ring finger protein 217 8121825 −0.620970732
PCMTD1 protein-L-isoaspartate (D-aspartate) O-methyltransferase domain
containing 1
8150714 −0.635640315
NKTR natural killer-tumor recognition sequence 8079079 −0.63772807
KIF23 kinesin family member 23 7984540 −0.649229354
PRPF40A PRP40 pre-mRNA processing factor 40 homolog A (S. cerevisiae) 8055913 −0.652162751
− − 8098287 −0.658215787
ARID4A AT rich interactive domain 4A (RBP1-like) 7974621 −0.661691075
LUC7L3 LUC7-like 3 (S. cerevisiae) 8008493 −0.663829187
NIPBL Nipped-B homolog (Drosophila) 8104944 −0.6642255
CENPE centromere protein E, 312kDa 8102076 −0.664227054
BOD1L biorientation of chromosomes in cell division 1-like 8099410 −0.665905703
TAF1D TATA box binding protein (TBP)-associated factor, RNA polymerase I,
D, 41kDa
7951008 −0.668975157
PIBF1 progesterone immunomodulatory binding factor 1 7969390 −0.670731182
SENP6 SUMO1/sentrin specific peptidase 6 8120758 −0.675080818
SMC2 structural maintenance of chromosomes 2 8156982 −0.681747538
DNAJC10 DnaJ (Hsp40) homolog, subfamily C, member 10 8046759 −0.690820266
ZNF638 zinc finger protein 638 8042601 −0.696757481
STXBP3 syntaxin binding protein 3 7903541 −0.698824428
TTK TTK protein kinase 8120838 −0.699258503
SCYL2 SCY1-like 2 (S. cerevisiae) 7957806 −0.710364273
ERBB2IP erbb2 interacting protein 8105681 −0.71178458
CHD1 chromodomain helicase DNA binding protein 1 8113305 −0.71533841
MPP6 membrane protein, palmitoylated 6 (MAGUK p55 subfamily
member 6)
8131927 −0.715467135
C1orf27 chromosome 1 open reading frame 27 7908330 −0.715867564
DNM1L dynamin 1-like 7954752 −0.716232722
CEP152 centrosomal protein 152kDa 7988537 −0.717688618
OTUD6B OTU domain containing 6B 8147262 −0.735794509
ATRX alpha thalassemia/mental retardation syndrome X-linked (RAD54
homolog, S. cerevisiae)
8173673 −0.740293061
ZNF100 zinc finger protein 100 8035808 −0.741413733
KIF18A kinesin family member 18A 7947248 −0.743358618
DEK DEK oncogene 8124144 −0.744034441
− − 8083445 −0.766235985
− − 8119580 −0.77576534
SDCCAG1 serologically defined colon cancer antigen 1 7978866 −0.776418378
ANKRD36B ankyrin repeat domain 36B 8054064 −0.777582301
ANKRD26 ankyrin repeat domain 26 7932637 −0.779453671
LYSMD3 LysM, putative peptidoglycan-binding, domain containing 3 8113064 −0.780972234
CTAGE4 /// CTAGE6 /// LOC100142659
/// LOC441294 /// hCG_2030429
CTAGE family, member 4 /// CTAGE family, member 6 /// CTAGE
family member /// similar to CTAGE6 /// CTAGE family, member 4-like
8136979 −0.78257421
SUCLA2 succinate-CoA ligase, ADP-forming, beta subunit 7971541 −0.78881152
SMC5 structural maintenance of chromosomes 5 8155770 −0.795143951
(Continued)
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Gene symbol Gene name Probe ID Log2 fold change
POLK polymerase (DNA directed) kappa 8106303 −0.814486061
ERGIC2 ERGIC and golgi 2 7962013 −0.820896474
RAD50 RAD50 homolog (S. cerevisiae) 8107942 −0.827079801
THOC2 THO complex 2 8174893 −0.836189906
KTN1 kinectin 1 (kinesin receptor) 7974483 −0.866627304
JMJD1C jumonji domain containing 1C 7933877 −0.86686842
USP15 ubiquitin specific peptidase 15 7956670 −0.869012602
PPP1R12A protein phosphatase 1, regulatory (inhibitor) subunit 12A 7965123 −0.883024382
FNBP1L formin binding protein 1-like 7903092 −0.886872231
SMC6 structural maintenance of chromosomes 6 8050443 −0.915161746
SMC4 structural maintenance of chromosomes 4 8083709 −0.920861102
ROCK2 Rho-associated, coiled-coil containing protein kinase 2 8050302 −0.924567683
AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 8134122 −0.935693684
ZNF252 zinc finger protein 252 8153935 −0.939582046
COPS2 COP9 constitutive photomorphogenic homolog subunit 2
(Arabidopsis)
7988605 −0.975928968
GCC2 GRIP and coiled-coil domain containing 2 8044236 −1.024026926
CTAGE4 /// CTAGE6 /// LOC100142659
/// LOC441294 /// hCG_2030429
CTAGE family, member 4 /// CTAGE family, member 6 /// CTAGE
family member /// similar to CTAGE6 /// CTAGE family, member 4-like
8129560 −1.025580319
ROCK1 Rho-associated, coiled-coil containing protein kinase 1 8022441 −1.074633032
FLJ45950 FLJ45950 protein 7952673 −1.131057985
Table 4 | Significantly up- and down-regulated top molecules in the control vs. the depressed group (− = reduction in expression levels).
Gene symbol Gene title log2 fold change P-value
VTRNA1-2 vault RNA 1-2 2.28 0.026
PGF Placenta growth factor 0.70 0.013
RNH1 ribonuclease/angiogenin inhibitor 1 0.57 0.036
ITPK1 inositol 1,3,4-triphosphate 5/6 kinase 0.55 0.037
Mir-503 microRNA 503 0.52 0.047
RAD23A RAD23 homolog A (S. cerevisiae) 0.52 0.013
APOC1 apolipoprotein C-I 0.50 0.037
USP15 ubiquitin specific peptidase 15 −0.87 0.026
PPP1R12A protein phosphatase 1. regulatory (inhibitor) subunit 12A −0.88 0.021
FNBP1L formin binding protein 1-like −0.89 0.046
SMC6 structural maintenance of chromosomes 6 −0.92 0.026
SMC4 structural maintenance of chromosomes 4 −0.92 0.024
ROCK2 Rho-associated. coiled-coil containing protein kinase 2 −0.92 0.021
AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 −0.94 0.028
COPS2 COP9 constitutive photomorphogenic homolog subunit 2 (Arabidopsis) −0.98 0.008
GCC2 GRIP and coiled-coil domain containing 2 −1.02 0.019
ROCK1 Rho-associated. coiled-coil containing protein kinase 1 −1.07 0.028
2.53] and KTN1 [F(1, 44) = 1.57]). When the placental gene
expression was compared between antidepressant-treated women
and controls (Figure 2B), we found a significant down-regulation
of ROCK1 [F(1, 47) = 4.26, P < 0.05], ROCK2 [F(1, 46) = 9.48,
P < 0.01], GCC2 [F(1, 47) = 3.78, p = 0.05], KTN1 [F(1, 46) =
6.31, P < 0.05], DNM1L [F(1, 47) = 6.40, P < 0.05], and a ten-
dency for down-regulation of C12orf39 [F(1, 47) = 3.39, P =
0.07]. The gene expression of NEXN [F(1, 47) = 1.28, ns] did not
differ between antidepressant-treated women and controls.
DISCUSSION
We performed a gene expression study in the fetal placenta of
depressed women and antidepressant-treated women, and com-
pared them with the gene expression of the placentas from
women with normal pregnancies. We found that antenatal
depression and antidepressant exposure during pregnancy has
an influence on the gene expression of the placenta. In the
microarray 108 genes were differentially expressed in women
with antenatal depression, while 109 genes were differentially
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FIGURE 1 | Visualization of differentially expressed genes using hierarchical clustering of genes in depressed (A) and SSRI-treated (B) vs. control fetal
placentas.
Table 5 | Enriched ingenuity pathway analysis (IPA) categories including differentially expressed genes in the depressed group.





ARID4A (p = 0.037); ATRX (p = 0.049); EIF5B (p = 0.021); JMJD1C
(p = 0.034); KIF23 (p = 0.028); KIF18A (p = 0.039); LRP2
(p = 0.039); NAP1L1 (p = 0.044); NCKAP1 (p = 0.043); PDE3B
(p = 0.040); RAD23A (p = 0.013); SMC2 (p = 0.034); SMC4
(p = 0.024); SMC5 (p = 0.011); SMC6 (p = 0.026); TTK (p = 0.049)
27
Cell cycle, cancer, connective
tissue disorders
CHD1 (p = 0.026); CHD9 (p = 0.026); DNAJC10 (p = 0.028); FZD6
(p = 0.018); HOMER1 (p = 0.048); N4BP2L2 (p = 0.029); NIPBL
(p = 0.046); PTBP2 (p = 0.041); SKIV2L2 (p = 0.041); SNAPC1





immune cell T rafficking
CENPE (p = 0.026); COPS2 (p = 0.008); LUC7L3 (p = 0.026);
MPP6 (p = 0.034); OTUD6B (p = 0.046); PIBF1 (p = 0.044); ROCK1
(p = 0.023); SENP6 (p = 0.021); SENP7 (p = 0.023); STXBP3







APOC1 (p = 0.034); CHRM3 (p = 0.021); DEK (p = 0.039); DNM1L
(0.048); ERBB2IP (0.025); PGF (p = 0.013); PPP1R12A (p = 0.021);





DGKH (p = 0.026); FNBP1L (p = 0.046); KTN1 (p = 0.021); NKTR
(p = 0.046); RNF19A (p = 0.048); THOC2 (p = 0.028)
9
Table 6 | Canonical pathway analysis of the depressed group.
Canonical pathway Genes P-value
Actin nucleation by ARP-WASP complex PPP1R12A, ROCK1, ROCK2 0.003
RhoA signaling KTN1, PPP1R12A, ROCK1, ROCK 2 0.029
VEGF signaling PGF, ROCK1, ROCK2 0.011
Protein kinase A signaling AKAP9, ANAPC4, PDE3B, PPP1R12A, ROCK1, ROCK2 0.011
1D-myo-inositol Hexakisphosphate Biosynthesis V (from Ins(1,3,4)P3) ITPK1 0.015
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Table 7 | Significantly up and down regulated genes in the control vs. SSRI groups (− = reduction in expression levels).
Gene symbol Gene name Probe ID Log2 fold change
C12orf39 chromosome 12 open reading frame 39 7954398 1.274830514
FLJ34503 hypothetical FLJ34503 8121569 1.266115442
RNU4-1 /// RNU4-1B RNA, U4 small nuclear 1 /// RNA, U4 small nuclear 1B 7967030 0.911924177
KRTAP19-8 keratin associated protein 19-8 8069876 0.821169613
OR2A7 /// OR2A4 /// LOC728377 olfactory receptor, family 2, subfamily A, member 7 /// olfactory receptor,
family 2, subfamily A, member 4 /// similar to rho guanine nucleotide
exchange factor 5
8143633 0.791137617
KRT81 keratin 81 7963353 0.778243623
OR2A7 /// OR2A4 /// LOC728377 olfactory receptor, family 2, subfamily A, member 7 /// olfactory receptor,
family 2, subfamily A, member 4 /// similar to rho guanine nucleotide
exchange factor 5
8129558 0.774018568
RNU4-2 RNA, U4 small nuclear 2 7967028 0.707367007
− − 7899484 0.693169774
SERINC2 serine incorporator 2 7899615 0.641601416
APLN apelin 8175016 0.632933192
ANGPTL4 angiopoietin-like 4 8025402 0.61857093
TUBA1C tubulin, alpha 1c 7955179 0.558532616
− − 8139128 0.546472497
S100A3 S100 calcium binding protein A3 7920278 0.543186629
LOC100127980 hypothetical protein LOC100127980 8036302 0.540856558
TECR trans-2,3-enoyl-CoA reductase 8101622 0.539800494
SCARNA10 small Cajal body-specific RNA 10 7953383 0.537535155
RRAD Ras-related associated with diabetes 8001918 0.534226961
EFNA5 ephrin-A5 8113433 0.533194259
CDC42EP1 CDC42 effector protein (Rho GTPase binding) 1 8072817 0.529414661
PCTK1 PCTAIRE protein kinase 1 8167103 0.528119471
SNORD116-16 small nucleolar RNA, C/D box 116-16 7981980 0.525075622
− − 8130181 0.511027698
− − 7953128 0.508366155
ORMDL3 ORM1-like 3 (S. cerevisiae) 8014916 0.507840044
ARHGEF5 /// ARHGEF5L ///
LOC728377
Rho guanine nucleotide exchange factor (GEF) 5 /// Rho guanine
nucleotide exchange factor (GEF) 5-like /// similar to rho guanine
nucleotide exchange factor 5
8136987 0.503949491
MAP4K5 mitogen-activated protein kinase kinase kinase kinase 5 7978997 −0.503225433
FANCL /// VRK2 Fanconi anemia, complementation group L /// vaccinia related kinase 2 8052382 −0.503353866
AHCTF1 AT hook containing transcription factor 1 7925622 −0.503946371
ZNF280D zinc finger protein 280D 7989159 −0.505508381
SNX6 sorting nexin 6 7978570 −0.512758574
CBWD3 /// CBWD5 /// CBWD6 ///
LOC728877 /// CBWD7 ///
LOC653510 /// CBWD2
COBW domain containing 3 /// COBW domain containing 5 /// COBW
domain containing 6 /// similar to COBW domain containing 3 /// COBW
domain containing 7 /// similar to COBW domain containing 1 /// COBW
domain containing 2
8155422 −0.513922351
PHF20L1 PHD finger protein 20-like 1 8148358 −0.514646483
FAS Fas (TNF receptor superfamily, member 6) 7929032 −0.527079798
METTL14 methyltransferase like 14 8097066 −0.531709394
ZNF100 zinc finger protein 100 8035808 −0.534310441
RGPD2 /// RGPD5 /// RGPD8 ///
RGPD3 /// RGPD4 /// RGPD6 ///
RGPD1 /// RANBP2
RANBP2-like and GRIP domain containing 2 /// RANBP2-like and GRIP
domain containing 5 /// RANBP2-like and GRIP domain containing 8 ///
RANBP2-like and GRIP domain containing 3 /// RANBP2-like and GRIP
domain containing 4 /// RANBP2-like and GRIP domain containing 6 ///
RANBP2-like and GRIP domain containing 1 /// RAN binding protein 2
8044161 −0.543369485
SHOC2 soc-2 suppressor of clear homolog (C. elegans) 7930470 −0.550070146
IRAK1BP1 interleukin-1 receptor-associated kinase 1 binding protein 1 8120826 −0.550763514
VAMP7 vesicle-associated membrane protein 7 8171041 −0.554437451
(Continued)
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Table 7 | Continued
Gene symbol Gene name Probe ID Log2 fold change
VAMP7 vesicle-associated membrane protein 7 8176962 −0.554437451
ZNF791 zinc finger protein 791 8026007 −0.55599566
GOLGB1 golgin B1, golgi integral membrane protein 8089930 −0.559994665
RGPD2 /// RGPD5 /// RGPD8 ///
RGPD3 /// RGPD4 /// RGPD6 ///
RGPD7 /// RGPD1 /// RANBP2
RANBP2-like and GRIP domain containing 2 /// RANBP2-like and GRIP
domain containing 5 /// RANBP2-like and GRIP domain containing 8 ///
RANBP2-like and GRIP domain containing 3 /// RANBP2-like and GRIP
domain containing 4 /// RANBP2-like and GRIP domain containing 6 ///
RANBP2-like and GRIP domain containing 7 /// RANBP2-like and GRIP
domain containing 1 /// RAN binding protein 2
8044304 −0.562605545
FAM133B /// LOC728640 ///
LOC728153
family with sequence similarity 133, member B /// family with sequence
similarity 133, member B pseudogene /// similar to FAM133B protein
8105504 −0.56577534
STK17B serine/threonine kinase 17b 8057887 −0.565889797
− − 8054532 −0.568088762
PCM1 pericentriolar material 1 8144812 −0.574364755
POLK polymerase (DNA directed) kappa 8106303 −0.576549694
− − 8147650 −0.578295577
C1orf58 chromosome 1 open reading frame 58 7909931 −0.580015227
RGPD1 /// RGPD2 /// RGPD5 ///
RGPD8 /// RGPD3 /// RGPD4 ///
RGPD6 /// RGPD7 /// RANBP2
RANBP2-like and GRIP domain containing 1 /// RANBP2-like and GRIP
domain containing 2 /// RANBP2-like and GRIP domain containing 5 ///
RANBP2-like and GRIP domain containing 8 /// RANBP2-like and GRIP
domain containing 3 /// RANBP2-like and GRIP domain containing 4 ///
RANBP2-like and GRIP domain containing 6 /// RANBP2-like and GRIP
domain containing 7 /// RAN binding protein 2
8054414 −0.582592072
RGPD2 /// RGPD5 /// RGPD8 ///
RGPD3 /// RGPD4 /// RGPD6 ///
RGPD7 /// RGPD1 /// RANBP2
RANBP2-like and GRIP domain containing 2 /// RANBP2-like and GRIP
domain containing 5 /// RANBP2-like and GRIP domain containing 8 ///
RANBP2-like and GRIP domain containing 3 /// RANBP2-like and GRIP
domain containing 4 /// RANBP2-like and GRIP domain containing 6 ///
RANBP2-like and GRIP domain containing 7 /// RANBP2-like and GRIP
domain containing 1 /// RAN binding protein 2
8054676 −0.586951747
RANBP2 RAN binding protein 2 8044263 −0.589348972
− − 8054557 −0.592061813
MNS1 meiosis-specific nuclear structural 1 7989146 −0.595349364
DNAJC13 DnaJ (Hsp40) homolog, subfamily C, member 13 8082688 −0.601103633
BDP1 B double prime 1, subunit of RNA polymerase III transcription initiation
factor IIIB
8106025 −0.601882298
NKTR natural killer-tumor recognition sequence 8079079 −0.602491778
ARID4A AT rich interactive domain 4A (RBP1-like) 7974621 −0.602522967
CBWD3 /// CBWD5 /// CBWD6 ///
CBWD7 /// LOC653510 ///
CBWD2 /// CBWD1
COBW domain containing 3 /// COBW domain containing 5 /// COBW
domain containing 6 /// COBW domain containing 7 /// similar to COBW
domain containing 1 /// COBW domain containing 2 /// COBW domain
containing 1
8161575 −0.605839737
BDP1 B double prime 1, subunit of RNA polymerase III transcription initiation
factor IIIB
8177560 −0.608777219
− − 7942645 −0.611731094
JMJD1C jumonji domain containing 1C 7933877 −0.612753894
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 7961710 −0.613240551
C15orf5 chromosome 15 open reading frame 5 7990636 −0.631000244
LAMA4 laminin, alpha 4 8128991 −0.636829539
FAM133B /// LOC728640 family with sequence similarity 133, member B /// family with sequence
similarity 133, member B pseudogene
8055978 −0.63846971
PRPF40A PRP40 pre-mRNA processing factor 40 homolog A (S. cerevisiae) 8055913 −0.641694474
ERGIC2 ERGIC and golgi 2 7962013 −0.65241833
ZNF644 zinc finger protein 644 7917604 −0.664132951
CCDC88A coiled-coil domain containing 88A 8052269 −0.673093507
(Continued)
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Gene symbol Gene name Probe ID Log2 fold change
LYSMD3 LysM, putative peptidoglycan-binding, domain containing 3 8113064 −0.675591155
LRRCC1 leucine rich repeat and coiled-coil domain containing 1 8147079 −0.676201087
ZNF146 zinc finger protein 146 8028186 −0.679184287
DNTTIP2 deoxynucleotidyltransferase, terminal, interacting protein 2 7917771 −0.687693256
− − 8167910 −0.688561865
GBP3 /// LOC400759 /// GBP1 guanylate binding protein 3 /// interferon-induced guanylate-binding
protein 1 pseudogene /// guanylate binding protein 1,
interferon-inducible, 67kDa
7917516 −0.690433417
CEP290 centrosomal protein 290kDa 7965264 −0.694219538
ABCE1 ATP-binding cassette, sub-family E (OABP), member 1 8097647 −0.696244083
MMRN1 multimerin 1 8096415 −0.703832221
CCDC55 coiled-coil domain containing 55 8006112 −0.709824621
− − 7989309 −0.71000087
ZNF260 zinc finger protein 260 8036324 −0.712626342
KTN1 kinectin 1 (kinesin receptor) 7974483 −0.712691264
DNM1L dynamin 1-like 7954752 −0.713859601
FER fer (fps/fes related) tyrosine kinase 8107208 −0.716049908
SDCCAG1 serologically defined colon cancer antigen 1 7978866 −0.717656644
ZNF254 zinc finger protein 254 8027368 −0.723859521
ECHDC1 enoyl Coenzyme A hydratase domain containing 1 8129379 −0.730176629
ZNF518A zinc finger protein 518A 7929562 −0.730789996
SLK STE20-like kinase (yeast) 7930276 −0.731081254
RAD50 RAD50 homolog (S. cerevisiae) 8107942 −0.732319601
ROCK2 Rho-associated, coiled-coil containing protein kinase 2 8050302 −0.73784498
CEP170 centrosomal protein 170kDa 7925525 −0.756625495
− − 8047401 −0.771296325
ANKRD12 ankyrin repeat domain 12 8020068 −0.777177689
ZNF721 /// ABCA11P zinc finger protein 721 /// ATP-binding cassette, sub-family A (ABC1),
member 11 (pseudogene)
8098758 −0.777277839
ROCK1 Rho-associated, coiled-coil containing protein kinase 1 8022441 −0.804644966
AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 8134122 −0.83694096
SYCP2 synaptonemal complex protein 2 8067305 −0.866613383
EEA1 early endosome antigen 1 7965436 −0.883045052
LOC400986 /// ANKRD36B ///
ANKRD36 /// LOC100289777 ///
LOC100133923 /// FLJ40330
protein immuno-reactive with anti-PTH polyclonal antibodies /// ankyrin
repeat domain 36B /// ankyrin repeat domain 36 /// hypothetical protein
LOC100289777 /// hypothetical protein LOC100133923 /// hypothetical
LOC645784
8053801 −0.883294274
COPS2 COP9 constitutive photomorphogenic homolog subunit 2 (Arabidopsis) 7988605 −0.883531246
GCC2 GRIP and coiled-coil domain containing 2 8044236 −0.919095326
− − 8084878 −0.91918252
NEXN nexilin (F actin binding protein) 7902495 −1.000773069
− − 8098287 −1.149966378
expressed in antidepressant-treated women. Only 20 genes were
overlapping between depressed women and women on antide-
pressant treatment. Among the genes we chose for valida-
tion, only 2 were validated with qPCR for depressed women.
In the antidepressant-treated women, 6 genes were validated,
indicating a more robust effect in alterations of these genes due
to antidepressant treatment during pregnancy.
Antenatal depression is a relatively heterogeneous condition
with different causes (primary or secondary to somatic disease)
and differential degree of endocrine disturbances. Furthermore,
women with antenatal depression may also differ between the
pilot microarray and the validation study as to depression sever-
ity and duration of the depressive episode. These factors may have
precluded the possibility to confirm the microarray findings, and
it is a major limitation that not all women in the validation part of
the study were diagnosed by a structured psychiatric interview. As
depression per se has effects on perinatal outcomes such as birth
weight and gestational age (Chambers et al., 1996), suggesting
that placental function is altered, further studies in more homo-
geneous women (and with larger sample sizes) of depression are
warranted. In addition, women on antidepressant treatment dur-
ing pregnancy possibly may have had a more severe depression,
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Table 8 | Significantly up- and down-regulated top molecules in the control vs. SSRI group (- = reduction in expression levels).
Gene symbol Gene title log2 Fold change P-value
C12orf39 chromosome 12 open reading frame 39 1.28 0.009
RNU4-1 RNA, U4 small nuclear 1 0.91 0.026
KRT81 keratin 81 0.78 0.007
RNU4-2 RNA, U4 small nuclear 2 0.71 0.043
SERINC2 serine incorporator 2 0.64 0.038
APLN apelin 0.63 0.014
ANGPTL4 angiopoietin-like 4 0.62 0.047
TUBA1C tubulin, alpha 1c 0.56 0.027
S100A3 S100 calcium binding protein A3 0.54 0.042
TECR trans-2,3-enoyl-CoA reductase 0.54 0.048
ANKRD12 ankyrin repeat domain 12 −0.78 0.042
ZNF721 zinc finger protein 721 −0.78 0.033
ROCK1 Rho-associated, coiled-coil containing protein kinase 1 −0.80 0.041
AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 −0.84 0.017
SYCP2 synaptonemal complex protein 2 −0.87 0.042
EEA1 early endosome antigen 1 −0.88 0.015
ANKRD36B ankyrin repeat domain 36B −0.88 0.041
COPS2 COP9 constitutive photomorphogenic homolog subunit 2 (Arabidopsis) −0.88 0.007
GCC2 GRIP and coiled-coil domain containing 2 −0.92 0.032
NEXN nexilin (F actin binding protein) −1.00 0.044
Table 9 | Enriched ingenuity pathway analysis (IPA) categories including differentially expressed genes in the SSRI group.
IPA network top 5 Genes IPA score
Infectious disease, cellular
assembly and organization,
cellular function and maintenance
ARHGEF5 (p = 0.017); ARID4A (p = 0.041); CDK16 (p = 0.023);
DNAJC13 (p = 0.036); EFNA5 (p = 0.027); GBP1 (p = 0.027);
IRAK1BP1 (p = 0.022); KTN1 (p = 0.016); MMRN1 (p = 0.045);
NKTR (p = 0.017); PRPF40A (p = 0.017); RANBP2 (p = 0.034);
SNX6 (p = 0.033)
13
Cellular growth and proliferation,
inflammatory response, lipid
metabolism
AKAP9 (p = 0.017); ANGPTL4 (p = 0.047); APLN (p = 0.014);
CDC42EP1 (p = 0.041); COPS2 (p = 0.007); FAS (p = 0.038);
KRT81 (p = 0.007); MAP4K5 (p = 0.040); ROCK1 (p = 0.041);
TUBA1C (p = 0.027); ZNF146 (p = 0.035)
11
Cell death and survival,
inflammatory response, cellular
movement
ANKRD12 (p = 0.042); BDP1 (p = 0.038); CCDC88A (p = 0.048);
DNM1L (p = 0.015); FANCL (p = 0.048); FER (p = 0.042); JMJD1C
(p = 0.028); ROCK2 (p = 0.027); S100A3 (p = 0.042)
9
Cell death and survival, liver
necrosis/cell death, hematological
system development and function
ABCE1 (p = 0.016); CEP170 (p = 0.048); EEA1 (p = 0.015); LAMA4
(p = 0.027); MNS1 (p = 0.009); RNU4-1 (p = 0.026); RRAD






NEXN (p = 0.044) 2
since continued treatment apparently was needed, and that this
effect is reflected in the gene expression pattern. However, it is
also possible that alterations in placental gene expression already
occur because of the antenatal depression, but become (more)
apparent, when antidepressants are used. Although several alter-
ations in the gene expression of the fetal placenta were found, it
remains to establish if these alterations are found in the fetus as
well.
When the microarray was validated with a larger sample-size,
ROCK2 was down-regulated in both depressed and SSRI-treated
women. ROCK1 and ROCK2 are part of the Rho-associated
coiled-coil kinase family (Nakagawa et al., 1996; Amano et al.,
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Table 10 | Canonical pathway analysis of the SSRI group.
Canonical pathway Genes P-value
Ephrin A signaling EFNA5, ROCK1, ROCK2 0.001
RhoA signaling CDC42EP1, KTN1,ROCK1, ROCK2 0.002
PEDF signaling FAS, ROCK1, ROCK2 0.004
Breast cancer regulation by Stathmin 1 ARHGEF5, ROCK1, ROCK2, TUBA1C 0.012
Signaling by Rho Family GTPases ARHGEF5,CDC42EP1, ROCK1, ROCK2 0.021
Table 11 | Genes commonly altered in depressed and SSRI groups compared with controls. (− = reduction in expression levels).
Gene name Gene symbol Probe Set ID Log2 Fold change
SSRI Depressed
jumonji domain containing 1C JMJD1C 7933877 −0.612753894 −0.86686842
dynamin 1-like DNM1L 7954752 −0.713859601 −0.716232722
ERGIC and golgi 2 ERGIC2 7962013 −0.65241833 −0.820896474
kinectin 1 (kinesin receptor) KTN1 7974483 −0.712691264 −0.866627304
AT rich interactive domain 4A (RBP1-like) ARID4A 7974621 −0.602522967 −0.661691075
serologically defined colon cancer antigen 1 SDCCAG1 7978866 −0.717656644 −0.776418378
COP9 constitutive photomorphogenic homolog subunit 2 (Arabidopsis) COPS2 7988605 −0.883531246 −0.975928968
Rho-associated, coiled-coil containing protein kinase 1 ROCK1 8022441 −0.804644966 −1.074633032
zinc finger protein 146 ZNF146 8028186 −0.679184287 −0.584609444
zinc finger protein 100 ZNF100 8035808 −0.534310441 −0.741413733
GRIP and coiled-coil domain containing 2 GCC2 8044236 −0.919095326 −1.024026926
Rho-associated, coiled-coil containing protein kinase 2 ROCK2 8050302 −0.73784498 −0.924567683
PRP40 pre-mRNA processing factor 40 homolog A (S. cerevisiae) PRPF40A 8055913 −0.641694474 −0.652162751
natural killer-tumor recognition sequence NKTR 8079079 −0.602491778 −0.63772807
− − 8098287 −1.149966378 −0.658215787
polymerase (DNA directed) kappa POLK 8106303 −0.576549694 −0.814486061
RAD50 homolog (S. cerevisiae) RAD50 8107942 −0.732319601 −0.827079801
LysM, putative peptidoglycan-binding, domain containing 3 LYSMD3 8113064 −0.675591155 −0.780972234
A kinase (PRKA) anchor protein (yotiao) 9 AKAP9 8134122 −0.83694096 −0.935693684
PHD finger protein 20-like 1 PHF20L1 8148358 −0.514646483 −0.551986952
FIGURE 2 | Differences in gene expression (qPCR) between subsets
in the validation study of the microarray data. Log2 mean
normalized expression (MNE) is shown for the ROCK1, ROCK2, GCC2,
KTN1, DNM1L, NEXN, and C12orf39 genes in depressed (A) and
SSRI women (B). (A) ∗P = 0.05, #P = 0.08, (B) ∗P ≤ 0.05, ∗∗P < 0.01,
#P = 0.07.
2000) and are downstream effectors of RhoA-GTP. Rho-ROCK
signaling pathways are involved in the regulation of actin
cytoskeleton, cell migration and proliferation (Schofield and
Bernard, 2013). In mice, ROCK1 is highly expressed in the lung,
liver, spleen, kidney and testis, whereas ROCK2 is most abundant
in the brain and heart (Nakagawa et al., 1996; Di et al., 2000; Wei
et al., 2001). The role of the Rho/ROCK family in cardiovascular
diseases has been extensively studied (Shi andWei, 2013). Cardiac
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malformations (Diav-Citrin et al., 2008), including pulmonary
hypertension (Chambers et al., 1996, 2006; Källén and Olausson,
2008; Kieler et al., 2012), have also been reported in the SSRI-
exposed offspring. In the present study we found that ROCK2
was down-regulated in antidepressant-exposed placentas (and to
lesser extent in placentas of depressed women). Moreover, IPA
analysis revealed that SSRI treatment affects the “Cardiovascular
Disease, Skeletal and Muscular Disorders, Cardiovascular System
Development and Function” network. Furthermore, it seems that
the use of SSRIs intensifies the alterations in ROCK2 expres-
sion compared to depression. Due to lowered ROCK2 expression
found in the fetal placenta of antidepressant-treated women, it
is tempting to speculate that a normal expression of ROCK2 in
placenta is important for a normal function of the cardiovascular
system in the fetus.
Interestingly, we also found that NEXN was down-regulated
in antidepressant-treated women. NEXN is a Z-disk gene
which is associated with dilated cardiomyopathy (Hassel et al.,
2009). Hence, further studies are necessary to investigate the
effects of down-regulated placental NEXN and ROCK2 on the
development of the cardiovascular system in the fetus.
Besides the role of the Rho kinase pathway in cardiovascu-
lar diseases, a role has also been proposed for the modulation
of the placental vasculature. Although expression of ROCK1 and
ROCK2 was not different, a higher RhoA mRNA expression was
found in placentae from women who suffered from preeclamp-
sia compared with placentae from those that were normotensive
(Friel et al., 2008). Interestingly, the use of antidepressants have
been associated with an increased risk for preeclampsia (Palmsten
et al., 2012). In addition, normal ROCK1 and ROCK2 activity is
required for normal inner cell mass morphogenesis, which is of
importance for successful fetal development (Laeno et al., 2013).
These data indicate that antidepressant use, mainly SSRI, dur-
ing pregnancy may influence pregnancy complications and fetal
development, and that ROCK1 and ROCK 2may be involved with
these processes.
Another gene that was down-regulated in depressed women
and to a lesser extent in antidepressant-treated women is the
C12orf39. C12orf39 is mainly expressed in the placenta and brain,
suggesting that C12orf39 may function in these active secretory
tissues (Wan et al., 2010). With regard to its function, C12orf39
is mainly extracellular and located in the villous trophoblasts.
Trophoblasts are important in exchanges between the fetus and
the mother and possess endocrine activity, releasing hormones
that are important in the homoeostasis of pregnancy (Lunghi
et al., 2007). In addition, trophoblasts are involved with the
secretion of placental growth hormone and are related to the
development of the placenta (Zeck et al., 2008). Together, these
findings suggest that C12orf39 is implicated in the regulation of
placenta development by its role in the biological functions of
the trophoblasts and that antenatal depression during pregnancy
may influence this development. Of interest is the fact that in
antidepressant-treated women the effect is no longer significant,
which may indicate that antidepressants may restore the effects of
the depression-induced down-regulation of C12of39.
GCC2 is a peripheral membrane protein localized to the
trans-Golgi network (Luke et al., 2003) which is involved in the
maintenance of Golgi structure or transport vesicle tethering
(Brown et al., 2011). More research is needed to investigate the
effects of altered gene expression of GCC2 in the placenta on the
developing fetus.
Similarly, KTN1 encodes the full kinectin which is found in
the endoplasmic reticulum and is responsible for the transport
of vesicles along microtubules. KTN1 is mainly expressed in the
brain, liver, ovarian, and hematopoietic cells (Tran et al., 2002;
Bai et al., 2006). Of interest is that kinectin can interact with
RhoA (Hotta et al., 1996), and that the RhoA signaling pathway
is affected in the depressed and antidepressant-treated women. As
described before normal RhoA signaling is important to prevent
pregnancy complications. Possible consequences for the fetus due
to the down-regulation of KTN1 in the placenta remains to be
investigated.
The last gene that was validated was DNM1L, which is a
GTPase regulating the mitochondrial fission. In mice it was
shown that ablation of the DNM1L gene induced defects in
trophoblast giant cells and cardiomyocytes (Wakabayashi et al.,
2009). Moreover, brain-specific DNM1L ablation caused devel-
opmental defects in the cerebellum (Wakabayashi et al., 2009).
Although these results were found in knockout mice it is tempt-
ing to speculate that the down-regulation of theDNM1L found in
the antidepressant-treated womenmight have an effect on embry-
onic and brain development as well. However, again, this effect
remains to be established.
Despite the strengths of our study, such as the longitudinal
nature of the study and the information on the state of the moth-
ers mood at multiple time points, some limitations need to be
discussed. First, we investigated alterations in gene expression
of the fetal side of the placenta due to antenatal depression and
antidepressant treatment. The results of this study may give us an
indication on altered pathways in the placenta. However, the pla-
centa is a separate organ and is not part of the fetus itself, therefore
findings need to be replicated in the developing fetus. In humans
this is not easily feasible therefore experiments are ongoing in a
rodent study. Second, antenatal depression is a relatively hetero-
geneous condition and outcome of diagnoses and treatment plans
(before the women entered the study) were diagnosed by different
doctors which may have biased the outcome. As a result dosages
and types of medication may not have been appropriate for the
diagnosed depression. Nevertheless, all women did undergo the
EPDS screening providing comparable data between the groups
concerning the mood state at different time points during (and
after) pregnancy. Third, in the validation study we included dif-
ferent types of antidepressants, although they were mainly SSRIs,
this may have influenced the outcome of the gene expression in
the SSRI treatment group.
In conclusion, gene expression in the fetal placenta is altered
by antenatal depression and SSRI treatment. As more placental
genes alterations were validated in a larger subset of SSRI-treated
women compared to those with antenatal depression we con-
clude that for these subset of genes, the effects of SSRI-intake
during pregnancy are more robust. It remains to be established
how these differentially affected genes influence the development
of the child, and whether these differences are found in the fetus
as well.
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